Current Report Filing (8-k)
February 02 2018 - 9:12AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
January 29, 2018
Date of
Report
Q BioMed Inc.
(Exact
name of registrant as specified in its charter)
Nevada
|
333-193328
|
46-4013793
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
c/o Ortoli Rosenstadt LLP
|
|
10022
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(212) 588-0022
Registrant’s
telephone number, including area code
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 1.01
Entry into a Material Definitive Agreement.
On
February 1, 2018, we raised $5,478,000 of gross proceeds in a
public offering. In the offering, we sold an aggregate of 1,711,875
shares of our common stock and 1,711,875 warrants to purchase
shares of our common stock exercisable for five years at $3.20 per
share.
Roth
Capital Partners acted as lead placement agent and CIM Securities
acted as co-lead placement agent for the offering pursuant to a
Placement Agency Agreement entered into on January 29, 2018, the
form of which was included in our registration statement on Form
S-1/A no. 3 as filed with the U.S. Securities and Exchange
Commission on January 12, 2018 and which form is incorporated into
this filing. Pursuant to the terms of the Placement Agency
Agreement, we paid the placement agents commissions of
approximately $418,000. After the placement agents’
commissions and offering expenses, we netted approximately
$4,915,000. We also issued the placement agents warrants
exercisable for five years into 81,688 shares of our common stock
at $3.84 per share as additional consideration under the Placement
Agency Agreement.
We
intend to use the net proceeds from the offering to:
●
launch our
non-opioid FDA approved Strontium Chloride 89 USP Injection (SR89),
a therapeutic drug for the treatment of skeletal pain associated
with metastatic cancers,
●
focus on the
clinical planning and IND filing for a Phase 4 post-marketing study
to expand the indication of the approved SR89,
●
complete pre-IND
studies and the filing of an IND for a phase II/III clinical
program to test the efficacy of QBM-001, our product candidate for
the treatment of young children with a rare autistic spectrum
disorder that severely inhibits their ability to
communicate,
●
continue
development work on our novel chemotherapeutic drug for liver
cancer and
●
further the
optimization and pre-clinical testing of our glaucoma drug Man-01
for the treatment of open angle glaucoma.
We conducted the offering pursuant to a Registration Statement on
Form S-1 (File No. 333-222008), which was declared effective by the
Securities and Exchange Commission on January 12,
2018.
The foregoing description of the Placement Agency Agreement is not
complete and is qualified in its entirety by reference to the full
text of the Placement Agency Agreement, the form of which is
incorporated by reference hereto and was filed as Exhibit 1.1 to
the Company’s Amendment No. 3 to the Registration Statement
on Form S-1, which was filed with the Securities and Exchange
Commission on January 12, 2018.
Item 7.01
Regulation FD Disclosure.
On January 30, 2018, we issued a press release entitled “Q
BioMed Inc. Prices $5.5 Million Public Offering.” A copy of
the press release is furnished herewith as
Exhibit 99.1.
On February 1, 2018, we issued a press release entitled
“
Q Biomed Inc. Closes
$5.48 Million Public Offering.” A copy of the press release
is furnished herewith as Exhibit 99.2.
The information in this Item 7.01 of this Form 8-K is being
furnished and shall not be deemed “filed” for the
purposes of Section 18 of the Securities Exchange Act of 1934, or
otherwise subject to the liabilities of that
section. The information in this Item 7.01 of this Form
8-K also shall not be deemed to be incorporated by reference into
any filing under the Act or the Securities Exchange Act of 1934,
except to the extent that we specifically incorporate it by
reference.
Item 9.01
Financial Statements and Exhibits.
99.1
Press Release
entitled “Q BioMed Inc. Prices $5.5 Million Public
Offering”
99.2
Press Release
entitled “Q Biomed Inc. Closes $5.48 Million Public
Offering”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Q BioMed Inc.
|
Date: February 1, 2018
|
By: /s/
William Rosenstadt
Name:
William Rosenstadt
Title:
Chief Legal Officer
|
Q BioMed (CE) (USOTC:QBIO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Q BioMed (CE) (USOTC:QBIO)
Historical Stock Chart
From Oct 2023 to Oct 2024